Tumor necrosis factor-α inhibitor therapy and fetal risk: A systematic literature review

Renée M Marchioni, Gary R Lichtenstein

Abstract
Tumor necrosis factor-α inhibitors (anti-TNFs) are effective in the treatment of inflammatory bowel disease (IBD) recalcitrant to conventional medical therapy. As the peak incidence of IBD overlaps with the prime reproductive years, it is crucial to establish pharmacologic regimens for women of childbearing age that achieve effective disease control without posing significant fetal harm. A systematic literature review was performed to identify all human studies with birth outcomes data after maternal exposure to infliximab, adalimumab, or certolizumab pegol within 3 mo of conception or during any trimester of pregnancy. Live births, spontaneous abortions or stillbirths, preterm or premature births, low birth weight or small for gestational age infants, and congenital abnormalities were recorded. Fifty selected references identified 472 pregnancy exposures. The subsequent review includes general information regarding anti-TNF therapy in pregnancy followed by a summary of our findings. The benefits of biologic modalities in optimizing disease control during pregnancy must be weighed against the potential toxicity of drug exposure on the developing fetus. Although promising overall, there is insufficient evidence to prove absolute safety for use of anti-TNFs during pregnancy given the limitations of available data and lack of controlled trials.

INTRODUCTION
Inflammatory bowel disease (IBD) encompasses the diagnoses of Crohn’s disease (CD) and ulcerative colitis (UC). These are chronic relapsing gastrointestinal illnesses that involve proinflammatory molecules. The onset of IBD has a bimodal distribution with a higher peak in the younger population aged 15-30 years; fifty percent of patients afflicted by IBD are diagnosed before the age

© 2013 Baishideng. All rights reserved.

Key words: Tumor necrosis factor-α inhibitors; Pregnancy; Congenital abnormalities; Safety; Infliximab; Adalimumab; Certolizumab

Core tip: A systematic literature review was performed to identify all human studies with birth outcomes data after maternal exposure to infliximab, adalimumab, or certolizumab pegol within 3 mo of conception or during any trimester of pregnancy. After systematic literature review investigating tumor necrosis factor-α inhibitor therapy and fetal risk, there is insufficient evidence to prove absolute safety for the use of biologics (specifically infliximab, adalimumab, and certolizumab pegol) during pregnancy.

Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: A systematic literature review. World J Gastroenterol 2013; 19(17): 2591-2602 Available from: URL: http://www.wjgnet.com/1007-9327/full/v19/i17/2591.htm DOI: http://dx.doi.org/10.3748/wjg.v19.i17.2591
of 35\[5\]. Hence, the peak incidence for developing these conditions overlaps with the prime reproductive years\[6,7\].

Effective control of IBD is essential during pregnancy. Active disease or disease flares have been associated with adverse obstetrical outcomes\[8\]. About 50% of the pregnancies in North America are unplanned, and less than half of females realize their pregnancy status by week four of gestation\[9\]. Inadvertent fetal exposure to medications during the crucial stages of organogenesis is thus possible and common. For these reasons, preconception discussions addressing risks and benefits of pharmacologic therapy during pregnancy are clinically warranted for all patients of childbearing potential.

The decision to pursue or maintain certain drug regimens throughout the prenatal and pregnancy periods may pose a significant challenge; the risks of disease activity must be weighed against the potential side effects of medical therapy. Untreated disease may create greater risks to a pregnancy than the drugs themselves\[10\]. Identifying the safest management strategy is crucial, as medication use during pregnancy impacts maternal disease activity, fetal development, and pregnancy outcomes.

Tumor necrosis factor-\( \alpha \) (TNF-\( \alpha \)) is a pleiotropic cytokine that plays a role both in pregnancy and in the pathophysiology of inflammatory conditions including IBD. Mouse models have demonstrated that TNF-\( \alpha \) is one of several cytokines bearing a potent regulatory effect on early development\[11\]. It controls cyclooxygenases that affect blastocyst implantation, vascular permeability of the endometrium, and uterine deciduation\[12\]. TNF-\( \alpha \) also contributes to the process of labor by stimulating uterine contractions in conjunction with other inflammatory cytokines\[13\]. The production of TNF-\( \alpha \) increases throughout pregnancy and reaches a peak at the onset of labor. High levels of TNF-\( \alpha \) have been implicated in such pregnancy complications as infection and fetal growth retardation and have even been linked to early and unexplained spontaneous abortions\[14,15\].

There is a characteristic abundance of gut inflammation in IBD originating via various mechanisms at the cellular and subcellular levels. TNF-\( \alpha \) is a key cytokine in the development and perpetuation of this abnormal immune response\[16\]. Several studies support the heightened production of TNF-\( \alpha \) in the intestinal mucosa of patients with CD, and the levels are increased in both inflamed and histologically normal mucosa\[17,18\]. Increased TNF-\( \alpha \) has also been linked to such rheumatologic and dermatologic conditions as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.

TNF-\( \alpha \) inhibitors (anti-TNFs) are drugs that block the action of TNF-\( \alpha \) and neutralize its biologic effect. This class has demonstrated efficacy in controlling disease activity associated with various inflammatory conditions. Infliximab (IFX), adalimumab (ADA), and certolizumab pegol (CTZ) are three such synthetic antibodies available in the United States for the treatment of IBD. Of these, infliximab has been the most highly studied.

Recognizing the effects of maternal drug use on fetal development is an important aspect of providing care to pregnant patients and women of childbearing age with IBD. There is limited data, though, pertaining to the safety of biologic agents when used during pregnancy. The United States Food and Drug Administration (FDA) lists anti-TNF agents as category B drugs\[19,20\] (category B specifies that animal studies do not indicate fetal risk and there are no controlled studies in women or that animal studies have demonstrated adverse effects but controlled studies in women have failed to demonstrate risk). A recent consensus statement declared anti-TNF agents to be low risk during certain stages of pregnancy\[21\]. Some case reports and small case series reporting anti-TNF exposure and pregnancy outcomes have been published. However, large population-based studies are sparse, and there is a lack of prospective data in pregnant women. In addition, there is a relatively short number of post-marketing years since the advent of biologics, thus narrowing the safety information pool even further. The increasing use of antibody-based therapeutics fosters the need for further study in this group of patients.

A systematic literature review was performed to investigate fetal risks associated with maternal exposure to TNF-\( \alpha \) inhibitors (IFX, ADA, and CTZ) during pregnancy.

### SEARCH STRATEGY

The search strategy was developed with the assistance of a medical librarian. Databases searched included MEDLINE, EMBASE, SCOPUS, and BIOSIS Previews through November 2011 and were restricted to studies published in English and performed in humans. Structured searches were conducted using both medical subject heading terms and keyword/exploded terms as follows: ("congenital abnormalities" OR "congenital disorders") AND ("infliximab" OR "adalimumab" OR "certolizumab"). Titles and abstracts were screened for relevance; reference lists of the applicable publications were hand-searched to identify additional studies.

### ELIGIBILITY CRITERIA

Case reports, case series, or observational studies published in article or abstract form were eligible for inclusion if there was documented female exposure to IFX, ADA, or CTZ within three months of conception or during any trimester of pregnancy and if > one of the following birth outcomes was assessed: live births, spontaneous abortions (SA), stillbirths (SB), preterm or premature births (PTB/PMB), low birth weight (LBW)/small for gestational age (SGA), or congenital abnormalities (CA). Studies were excluded if there was insufficient detail to link specific anti-TNF exposure with birth outcomes. One investigator independently performed the searches described above and reviewed the citations (titles and abstracts) to determine eligibility. Discrepancies were
Its efficacy in IBD has been documented in randomized
controlled trials in the treatment of moderate to severe CD refractory to conventional therapy as well as enterocutaneous fistulae. The drug can reduce the need for corticosteroids and, in patients who respond to initial dosing, IFX is effective for the maintenance of response and prolonged remission in CD.

IFX is classified by the United States FDA as pregnancy category B. Murine models show no evidence of teratogenicity or embryotoxicity. However, anti-TNF-α antibodies vary among species; data cannot simply be paralleled to human pregnancy outcomes. Infliximab does not cross-react with TNF-α in species other than humans and chimpanzees, and it has not been tested in animal reproduction studies.

IFX is not thought to cross the placenta in the first trimester due to its human IgG1 constant region, but this subclass is known to efficiently cross in the late second and third trimesters. Given this timing, the infant is somewhat shielded from drug exposure during the critical period of organogenesis. IFX levels can be detected in newborns of exposed mothers, and the drug remains in the system for up to six months after delivery. This bears important consequences in terms of newborn infection risks and vaccination responses. Discontinuing infliximab in the third trimester is an option to decrease late placental transport to the newborn.

**Infliximab**

Infliximab (Remicade) is a human-murine chimeric monoclonal antibody that neutralizes the activity of TNF-α. It is composed of a human immunoglobulin G1 constant region and a murine variable region. Its efficacy in IBD has been documented in randomized

data points from each study: anti-TNF drug exposure, indication for anti-TNF agent, pregnancy stage(s) of exposure by trimester, live births, and birth outcomes as aforementioned. Spontaneous abortions were defined as fetal death at < 20 wk, stillbirths as fetal death at > 20 wk or at weight > 500 g if gestational age unknown, preterm deliveries as < 37 wk gestation, premature deliveries as < 37 wk gestation and prior to completion of organ development, and low birth weight newborns as < 2500 g. Small for gestational age infants were described by authors as smaller than average size given the number of pregnancy weeks.

**SEARCH RESULTS**

The initial search yielded 11452 citations. Fifty studies (Table 1) met inclusion criteria for full review, including 13 case series, 36 case reports, and 2 prospective studies with control groups. Reports in Table 1 are categorized by biologic agent and study type, and details of maternal anti-TNF exposures and pregnancy outcomes are presented.

The total number of patients exposed to anti-TNFs was 472 (IFX 194/ADA 261/CTZ 17). Table 2 displays anti-TNF exposures and birth outcomes for the following categories: live births, spontaneous abortions, stillbirths, preterm/breath/mature births, low birth weight/ small for gestational age, and congenital abnormalities. Outcomes in Table 2 have been listed by anti-TNF exposure (IFX, ADA, and CTZ) and indication (for all medical conditions and for IBD patients alone), and results are compared to the general United States population.

Table 3 summarizes the reported congenital abnormalities associated with live births (4.1%). Among 19 congenital anomalies (IFX 9/ADA 10/CTZ 0), no specific pattern of birth defects was identified.

**DISCUSSION**

We performed a systematic literature review to assess the risk of adverse birth outcomes after maternal exposure to IFX, ADA, or CTZ and identified 50 references with a total of 472 fetal exposures.

The subsequent discussion highlights each biologic agent in the context of pregnancy and provides a summary of our data.

**Adalimumab**

Adalimumab (Humira) is a fully human monoclonal IgG1 antibody against TNF-α. It has proven effective for inducing and maintaining remission in CD, especially in those who have lost response to or have become intolerant of infliximab.

ADA is classified as an FDA pregnancy category B drug. In an embryo-fetal perinatal developmental toxicity study, cynomolgus monkeys were administered ADA at extreme dosages of up to 100 mg/kg (266 times human area under the curve (AUC) when dispersed as 40 mg subcutaneously with methotrexate weekly or 373 times human AUC when dispersed as 40 mg subcutaneously without methotrexate). No evidence of fetal harm due to ADA was recorded. Adequate and well-controlled studies have not been conducted in pregnant women. Again, animal reproduction and developmental studies are not always indicative of human response, and ADA must be used with caution in pregnancy. There is no long-term data regarding effects of adalimumab on the developing fetus.

Less information exists on the transplacental diffusion of ADA throughout the trimesters compared to infliximab. Determining the time course of drug administration and when to potentially discontinue ADA during pregnancy is not well-defined due to shorter dosing intervals and limited ability to commercially measure ADA levels. Withholding the drug in the third trimester may be considered to reduce late placental transport to the newborn. Mahadevan et al suggests discontinuation 8-10 wk prior to estimated date of delivery.
| Ref.                  | Study type | Disease          | Anti-TNF-α agent | Exposure to other drugs | Exposures in pregnancies with documented outcome | Maternal exposure: Pregnancy stage | Live births (n) | SA/SB (n) | PTB/PMB (n) | LBW/SGA (n) | CA (n) | Pregnancy outcomes: Details/complications |
|----------------------|------------|------------------|------------------|-------------------------|-----------------------------------------------|----------------------------------|--------------------|------------|-------------|-------------|--------|-----------------------------------------|
| Chambers et al[25]   | Prospective | RA               | IFX              | NS                      | 4 T1 T2/T3 other exposure details             | NS                              | 3                  | 1          | 5           |            |        | 1 preterm/premature birth due to placental detachment (31 wk, 1.6 kg with acute respiratory failure requiring mechanical ventilation × 24 h and intensive care × 40 d; healthy at 8 mo follow-up) |
| Mahadevan et al[26]  | Prospective | CD, UC           | IFX              | NS                      | 5 T1 T2/T3 other exposure details             | SA                              | 5                  |            |            |            |        | 1                     |
| Berthelot et al[27]  | Case series | Rheumatologic disease | IFX             |            | 3 C/T1: 1 C/T1/T2: 2                        | 3                               | 1                  |            |            |            |        |                                         |
| Chakravarty et al[28]| Case series | RA               | IFX              | Some pts               | 1 Pregnancy, not otherwise specified          | 1                               |                    |            |            |            |        |                                         |
| Correia et al[29]    | Case series | CD               | IFX              | Yes: 1                  | 2 C/T1/T2/T3                                | 2                               | 1                  | 1          | 1           | SGA        |        | 1                     |
| Hyrich et al[30]     | Case series | Rheumatologic disease | IFX             | Some pts               | 3 C/T1                                      | 2                               | 1                  |            |            |            |        |                                         |
| Kane et al[31]       | Case series | CD               | IFX              | Some pts               | 3 T1/T2/T3: 2 T2/T3: 3                      | 3                               |                    |            |            |            |        |                                         |
| Katz et al[32]       | Case series | CD: (82) UC: (1) RA: (8) JRA: (2) | IFX             | Some pts               | 100 C: 53 T1: 30 > 3 mo prior to C: 7        | 68                              | 10                 | 1          | 1           | 3          |        | 1 full-term with tetralogy of Fallot 1 intestinal malrotation 1 developmental delay and hypothyroidism 1 complicated neonatal course: Respiratory distress/jaundice/seizure. Mother was also exposed to several antibiotics for pulmonary and urinary infections, azathioprine, hydrocortisone, and total parental nutrition early in pregnancy Miscarriages (14): 10 SA 1 SB (mother exposed to leflunomide) 3 unknown type 1 neonatal jaundice (resolved) 1 complicated neonatal course: term delivery at 39 wk with respiratory distress/desaturation/gastric ulcer day 5; healthy at 6 mo follow-up 1 premature rupture of membranes |
| Unknown:(3)          |            |                  |                  |            |                                              |                                  |                    |            |            |            |        |                                         |
| Mahadevan et al[33]  | Case series | CD               | IFX              | Some pts               | 10 T1: 1 T3: 1 C/T1/T2/T3                    | 10                              | 3                  | 1          |            | LBW        |        | 1                     |
| Rosner et al[34]     | Case series | Rheumatologic disease | IFX      | Yes                   | 3 C/T1/T2/T3                                | 3                               | 1                  |            |            |            |        | 1                     |
| Schnitzler et al[35] | Case series | CD/UC/IC         | IFX              | NS                    | 10 C/T1/T2                                  | 9                               | 1                  | 2          |            |            |        |                                         |
| Author(s)                  | Type               | Disease                         | IFX | NS | C/T1/T2/T3 | 1  | 2  | 3  |
|---------------------------|--------------------|---------------------------------|-----|----|------------|----|----|----|
| Weber-Schoenderfer et al.  | Case series        |                                 | IFX | NS |            |    |    |    |
| Zelinkova et al.          | Case series        |                                 | IFX | NS |            |    |    |    |
| Akinci et al.             | Case report        | Rheumatologic disease           | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| Angelucci et al.          | Case report        | CD                              | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| Antoni et al.             | Case report        | Psoriatic Arthritis             | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| Atai et al.               | Case report        | CD                              | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| Atalar et al.             | Case report        | CD                              | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| Burt et al.               | Case report        | CD                              | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| Chaparro et al.           | Case report        | CD                              | IFX | NS | C/T1/T2/T3 | 1  |    |    |
| Cheent et al.             | Case report        | CD                              | IFX | NS | C/T1/T2/T3 | 1  |    |    |
| Epping et al.             | Case report        | CD                              | IFX | NS | C/T1/T2/T3 | 1  |    |    |
| Hou et al.                | Case report        | CD                              | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| James et al.              | Case report        | RA                              | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| Kinder et al.             | Case report        | RA                              | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| Østensen et al.           | Case report        | RA                              | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| Puig et al.               | Case report        | CD                              | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| Srinivasan et al.         | Case report        | CD                              | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| Skoennholdt et al.        | Case report        | UC                              | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| Songol et al.             | Case report        | CD                              | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| Tursi et al.              | Case report        | CD                              | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| Vasilaukas et al.         | Case report        | CD                              | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| Wilhauux et al.           | Case report        | AS                              | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| Xironchakis et al.        | Case report        | CD                              | IFX | Yes| C/T1/T2/T3 | 1  |    |    |
| Johnson et al.            | Prospective        | CD and RA                       | ADA | NS |            |    |    |    |

### Notes:
- **CA (2):** 1 ventricular septal defect
- **CA (1):** 1 growing hemangioma requiring therapy
- **SA:** L hand polydactyly
- **LBW:** Infant had respiratory depression after anesthesia that resolved spontaneously. Mother was taking methotrexate 2 mo prior to conception without folate acid supplement.
- **SGA:** Infant developed disseminated BCG after vaccination at 3 mo and died at 4.5 mo
- **SA:** Oligohydramnios detected on 18 wk ultrasound that resolved with discontinuation of Nimesulide.
- **SA:** Preterm premature birth (24 w k) complicated by intracerebral and intrapulmonary hemorrhages and neonate died at 3 d. Mother was also exposed to metronidazole, azathioprine, and mesalamine for fistulizing CD.
- **SA:** Preterm (29 w k) birth with neonatal hospitalization × 30 d post-delivery. Baby in ”good condition” at follow-up.
- **SA:** CA (7) (live births): 1 undescended testicle; 1 microcephaly; 1 congenital hip dysplasia with inguinal hernia; 1 congenital hypothyroidism; 1 ventricular septal defect.
| Author(s) | Type | Rheumatologic Disease | ADA | Specified Information | other Exposure Details |
|---|---|---|---|---|---|
| Berthelot et al. | Case series | Rheumatologic disease | ADA | Specified no exposure to disease-modifying anti-rheumatic drugs, methotrexate, or non-steroidal anti-inflammatory drugs; 3 Case reported by Srinivasan et al. was also documented by Katz et al. | 2 bicuspid aortic valve and agenesis of corpus callosum (twin sibling had patent ductus arteriosus) |
| Hyrich et al. | Case series | Rheumatologic disease | ADA | Some pts | 1 congenital hydronephrosis |
| Johnson et al. | Case series | CD and RA | ADA | NS | 1 spina bifida and hydrocephalus (resulted in elective termination) |
| | | | | | 1 ectopia cordis and caudal regression (twin pregnancy resulting in a spontaneous abortion) |
| Berthelot et al. | Case series | Rheumatologic disease | ADA | Specified no exposure to disease-modifying anti-rheumatic drugs, methotrexate, or non-steroidal anti-inflammatory drugs; 3 Case reported by Srinivasan et al. was also documented by Katz et al. | 2 bicuspid aortic valve and agenesis of corpus callosum (twin sibling had patent ductus arteriosus) |
| Hyrich et al. | Case series | Rheumatologic disease | ADA | Some pts | 1 congenital hydronephrosis |
| Johnson et al. | Case series | CD and RA | ADA | NS | 1 spina bifida and hydrocephalus (resulted in elective termination) |
| | | | | | 1 ectopia cordis and caudal regression (twin pregnancy resulting in a spontaneous abortion) |
| | | | | | 5 CA (5): |
| | | | | | 2 chromosomal abnormalities |
| | | | | | 1 atrial septal defect and peripheral pulmonic stenosis |
| | | | | | 1 ventricular septal defect |
| | | | | | 1 congenital hip dysplasia |

1 Specified no exposure to disease-modifying anti-rheumatic drugs, methotrexate, or non-steroidal anti-inflammatory drugs; 3 Case reported by Srinivasan et al. was also documented by Katz et al. Specified no exposure to disease-modifying anti-rheumatic drugs, methotrexate, or non-steroidal anti-inflammatory drugs. TNF: Tumor necrosis factor; CD: Crohn’s disease; UC: Ulcerative colitis; IC: Indeterminate colitis; RA: Rheumatoid arthritis; JRA: Juvenile rheumatoid arthritis; AS: Ankylosing spondylitis; IFX: Infliximab; ADA: Adalimumab; CTZ: Certolizumab pegol; NS: Not specified; Pts: Patients; C: Within < 3 mo prior to conception; T1: First trimester (LMP to 13 wk); T2: Second trimester (14 to 27 wk); T3: Third trimester (28 to 40 wk); SA: Spontaneous abortion; SB: Stillbirth; Preterm birth (< 37 wk gestation); PMB: Premature birth (< 37 wk gestation and prior to organ development); LBW: Low birth weight (< 2500 g); SGA: Small for gestational age (smaller than average size given the number of weeks of pregnancy).
The molecular structure of CTZ lacks an Fc portion, so its cross-placental transfer is different from that of IFX and ADA. The Fab’ fragment may passively cross the placenta in low levels during the first trimester, an event that is not expected with the IgG1 antibody. Although CTZ therapy would likely not need to be discontinued in the third trimester, it is important to recognize that the transplacental transfer of this drug occurs during a critical period of organogenesis in the first trimester.

In an animal model, pregnant rats received a murinized IgG1 TNF-α antibody and a PEGylated Fab’ fragment of the antibody. Lower levels of the drug were detected in the infant and in breast milk with the Fab’ fragment versus the full antibody\[87\]. Mahadevan et al\[88\] demonstrated these findings in two human patients receiving certolizumab during pregnancy. The drug was administered to both women two weeks prior to delivery. Although the mothers’ drug levels were higher on the date of delivery, newborn cord blood levels were low.

There are few published reports on the use of CTZ during pregnancy. As with the other anti-TNF agents, it is possible that the Fab’ fragment passively crosses the placenta at low levels in the first trimester. The drug must be further studied in humans to fully appreciate the course of drug transfer during gestation and subsequent effects on fetal development and pregnancy outcomes.

### SUMMARY OF DATA

Our review indicates that rates of SA and CA in anti-TNF-exposed patients are similar to rates in the general United States population\[74-76\] and in women with IBD unexposed to anti-TNF agents\[74-76\]. The live birth rate in the anti-TNF-exposed group (85.8%) is higher than that of the general United States population (64.6%); this holds true for all patients exposed to IFX or ADA regardless of underlying inflammatory disease and perhaps reflects a state of controlled disease activity. The live birth rate for patients exposed to CTZ (47.1%) is lower than that of the general population, although there is a very small collective sample size. The rates of SA and

### Table 2  Summary of anti-tumor necrosis factor exposures and birth outcomes  n (%)  

| Anti-TNF exposure | Fetal exposures | Birth outcomes, n (with relative percents) |
|-------------------|-----------------|------------------------------------------|
| IFX/ADA/CTZ total | 472 (85.8) | 32 (8.2) | 2 (0.6) | 41 (19.9) | 8 (6.1) | 19 (4.1) |
| IFX\[2\] | 194 (79.9) | 15 (6.1) | 2 (1.1) | 21 (26.9) | 5 (4.4) | 6 (4.0) |
| IFX in IBD\[3\] | 151 (77.5) | 11 (8.9) | 2 (1.4) | 16 (11) | 5 (4.8) | 4 (3.5) |
| ADA\[1\] | 261 | 242 (92.7) | 0 (0.0) | 20 (15.9) | 2 (28.6) | 13 (5.4) |
| ADA in IBD\[4\] | 224 | 210 (93.8) | 13 (5.8) | 0 (0.0) | 15 (17.0) | 2 (28.6) | 12 (5.7) |
| CTZ\[5\] | 17 | 8 (47.1) | 1 (5.9) | 0 (0.0) | 1 (12.5) | 0 (0.0) |
| CTZ in IBD\[6\] | 17 | 8 (47.1) | 1 (5.9) | 0 (0.0) | 1 (12.5) | 0 (0.0) |
| Outcome percents in US population\[69-73\] | 64.60% | 16.50% | 0.60% | 12.30% | 8.20% | 3.00%-5.00% |

1 Exposure in all reported medical conditions; 2 Exposure in inflammatory bowel disease (IBD) patients. TNF: Tumor necrosis factor; IFX: Infliximab; ADA: Adalimumab; CTZ: Certolizumab pegol; SA: Spontaneous abortion (fetal death at < 20 wk); SB: Stillbirth (fetal death at > 20 wk or > 350 g if gestational age unknown); PTB: Preterm birth (< 37 wk gestation); PMB: Premature birth (< 37 wk gestation and prior to completion of organ development); LBW: Low birth weight (< 2500 g); SGA: Small for gestational age (smaller than average size given number of pregnancy weeks).

### Table 3  Summary of congenital abnormalities reported  

| Congenital abnormalities (n = 19) | Affected (n) | Anti-TNF exposure |
|----------------------------------|-------------|-------------------|
| Ventricular septal defect | 3 | IFX (1), ADA (2) |
| Chromosomal abnormalities | 2 | IFX |
| Congenital hip dysplasia | 2 | IFX (1), ADA (1) |
| Intestinal malrotation | 1 | IFX |
| Congenital hypothyroidism | 1 | IFX |
| Hernia | 1 | IFX |
| L. hand polydactyly | 1 | IFX |
| Tetralogy of Fallot | 1 | IFX |
| Patent ductus arteriosus | 1 | ADA |
| Artrial septal defect and peripheral pulmonary stenosis | 1 | ADA |
| Bicuspid aortic valve and agenesis of corpus callosum | 1 | ADA |
| Primary craniosynostosis | 1 | ADA |
| Microcephaly | 1 | ADA |
| Congenital hydronephrosis | 1 | ADA |
| Undescended testes | 1 | ADA |

IFX: Infliximab; ADA: Adalimumab; TNF: Tumor necrosis factor.

### Certolizumab pegol

Certolizumab pegol (Cimzia) is a recombinant humanized anti-TNF-α fragment antigen binding (Fab’) fragment. The antibody fragment is bound to a polyethylene glycol molecule that extends the drug’s half-life to approximately two weeks in the plasma, thereby reducing dosing frequency\[85\]. Studies have demonstrated the efficacy of CTZ for induction and maintenance of remission in CD\[86\].

CTZ is a pregnancy category B drug. It does not cross-react with mouse or rat TNF-α. Reproduction studies in rats have thus been performed using a rodent anti-murine TNF-α pegylated Fab’ fragment (cTN3 PF) that is similar in function to CTZ. These studies have been conducted using doses up to 100 mg/kg and have revealed no evidence of impaired fertility or fetal adversities due to cTN3 PF. Adequate and well-controlled studies have not been performed in pregnant women. As animal reproduction studies are not always indicative of human response, this drug must be used with caution in pregnancy\[86\].
SB for all groups are similar to the general United States population[22] with the exception of IFX-exposed patients, in whom the rate of SB is just slightly higher. The PTB/PMB rate in the anti-TNF-exposed group (19.9%) is higher than in the United States population (12.3%)[22], perhaps due to an underlying predisposition as in the setting of IBD[23]. LBW/SGA infants are more common in ADA- and CTZ-exposed patients than in the general United States population[23], again possibly reflecting the underlying disease itself or the severity of disease activity.

In general, pregnancy does not increase the risk of disease exacerbation in CD or UC[24,25]. Approxiamtely one-third of women with inactive IBD at the time of conception are expected to flare during pregnancy and the puerperium[26]. Alternatively, if pregnancy overlaps with a period of active IBD, the disease may be difficult to control[27]. Active disease at the time of conception has been associated with increased rates of PTB[28] and fetal loss[29], and disease flares during pregnancy have been associated with PTB and LBW[30]. Studies are mixed regarding the risk of congenital malformations among IBD progeny, with some data showing an increased risk for both CD and UC patients[31] or for UC patients alone[32,33] and other data showing no increased risk in CD or UC[34,35]. Regardless of disease activity, women with IBD have an increased risk for such adverse pregnancy outcomes as PTB, SB, LBW, SGA, and delivery complications such as cesarean sections compared to the general population[36]. In our study, no discernible increased risks for SA or CA were identified. Overall, unless there is a clear risk of fetal harm (i.e., an FDA category X drug) that dictates otherwise, maintenance therapy is conventionally continued throughout pregnancy to optimize maternal disease control and prevent relapse or progression[37].

This systematic review has limitations. Pooling data from different studies yields inherent heterogeneity based on study designs, study populations, and recording of birth outcomes data. As evidenced, there are a limited number of reported pregnancy exposures to anti-TNF agents, many published as case reports or case series with small sample sizes; these do not necessarily reflect outcomes that can be extracted to the general population. Our review is affected by the limitations of the individual studies, including the inability to adjust for maternal disease activity and severity, comorbidities, or other maternal characteristics. Additionally, there exist potential publication bias against negative outcomes and recall bias involving drug exposure and timing of administration during conception and pregnancy. The decision to exclude studies based on the English language and on the inability to link specific anti-TNF exposure with birth outcomes may have dis-counted pertinent publications. Although care was taken to account for evident overlap, it is possible that repeated data exists given the nature of our information (for example, a case report that has also been reported within drug registry data).

A growing body of evidence supports that IFX, ADA, and CTZ are low risk in pregnancy[38], and studies beyond those included in our data set are underway to further elucidate fetal risk and optimal timing of bi-logic administration during pregnancy[39,40]. Thus far, it is believed that IFX and ADA are most compatible for use during conception and at least the first and second trimesters considering mechanisms of placental transport[41,42]. Further human data are needed to generate safety guidelines for the use of CTZ. In a recent study of pregnant women receiving biologic therapy, IFX and ADA were shown to be transplacentally transferred to infants at birth, with high levels of drug in cord blood and detectable drug levels up to six months after birth. CTZ was found to be least detectable in both cord blood and infant serum after birth. Of note, no CA or significant fetal complications were reported in this study[43].

Future efforts are promising and include the expansion of drug safety data registries and the development of larger prospective trials to help definitively quantify fetal risk and to facilitate clinical decision-making in treating women with IBD during their childbearing years. One such project is the highly anticipated Pregnancy IBD and Neonatal Outcomes study, a prospective data collection from multiple IBD centers in the United States[44]. This large cohort registry not only accounts for maternal factors including IBD activity, medication use, delivery methods, and pregnancy complications but also tracks data over time from the neonatal period through children's first year of life. Similarly, post-marketing surveillance data may uncover additional consequences of fetal exposure to biologic agents over time.

While evidence in the field is mounting, caution should indefinitely be exercised. Given the limitations of the available data and lack of controlled trials, there is insufficient evidence to prove absolute safety for use of anti-TNFs during pregnancy. Although the benefits of therapy in optimizing disease activity during gestation may lend to more favorable pregnancy outcomes based on a controlled disease state, definitive safety of drug exposure on the developing fetus has not been confirmed.

Medical management decisions during the preconception and pregnancy periods will inevitably vary by case based on respective risk-to-benefit ratios, details of disease activity, response to alternative therapies, and individual preferences. Women and men of childbearing age should be educated about the effects of IBD on pregnancy and the potential implications of treatment on fetal development. In addition, patients should be encouraged to discuss reproductive plans with their physicians in order to achieve remission prior to conceiving. Ideally, the primary preconception goal should be quiescent disease, as this lends to the most favorable pregnancy outcomes.

**CONCLUSION**

After systematic literature review investigating TNF-α inhibitor therapy and fetal risk, there is insufficient evi-
dence to prove absolute safety for the use of biologics (specifically infliximab, adalimumab, and certolizumab pegol) during pregnancy.

REFERENCES
1 Munkholm P. Crohn’s disease—occurrence, course and prognosis. An epidemiologic cohort-study. Dan Med Bull 1997; 44: 287-302 [PMID: 9233548]
2 Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28: 255-281, vii [PMID: 10372268]
9 Mosandrew M, Kane S. Inflammatory bowel diseases and management considerations: fertility and pregnancy. Curr Gastroenterol Rep 2009; 11: 395-399 [PMID: 1976367]
10 Leimkühler AM. [Psychosocial after care: studies of the value of psychosocial measures in clinical practice]. Fortschr Neurol Psychiat 1990; 58: 301-309 [PMID: 2172128]
17 Centers for Disease Control official website. Available from: URL: http://www.cdc.gov/reproductivehealth
18 Tartakovsky B, Ben-Yair E. Cytokine production during preimplantation development and pregnancy. Dev Biol 1991; 146: 345-352 [PMID: 1864460 DOI: 10.1016/0012-1606(91)90226-V]
19 Inseis HM, Zimmerman PD, Samuels P, Kniss DA. Tumour necrosis factor-alpha induces cyclo-oxygenase-2 gene expression in first trimester trophoblasts: suppression by glucocorticoids and NSAIDs. Placenta 1997; 18: 521-526 [PMID: 9290146 DOI: 10.1016/0143-4004(97)90005-4]
20 Daher S, Fonseca F, Ribeiro OG, Musatti CC, Gerbase-De Lima M. Tumor necrosis factor during pregnancy and at the onset of labor and spontaneous abortion. J Obstet Gynaecol Obstet Reprod Biol 1999; 83: 77-79 [PMID: 10221614 DOI: 10.1016/S0301-2115(98)00252-8]
23 Yu XV, Yan CF, Jin H, Li X. Tumor necrosis factor receptor 1 expression and early spontaneous abortion. Int J Gynaecol Obstet 2005; 88: 44-48 [PMID: 15617704 DOI: 10.1016/j.ijgo.2004.08.020]
24 Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs 2010; 24 Suppl 1: 3-14 [PMID: 21175228 DOI: 10.2165/11582090-000000000-00000]
25 Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, Poindron P, Duclos B. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn’s disease. Gut 1996; 39: 684-689 [PMID: 9026483 DOI: 10.1136/gut.39.5.684]
26 Riegel D, Büermann L, Gross KD, Luszik-Bhadra M, Mishra SN. Existence and stability of magnetic 3d moments in rare earth compounds. J Magn Magn Mater 2016; 444: 140-145 [PMID: 27288337 DOI: 10.1002/bips.201601860]
27 Infliximab (Remicade) package insert. Johnson & Johnson, Malvern: Centocor Ortho Biotech, 2005. Available from: URL: http://www.remicade.com
28 Adalimumum (Humira) package insert. North Chicago: Abbott Laboratories, 2007. Available from: URL: http://www.humira.com
29 Certolizumab pegol (Cimzia) package insert. Smyrna: UCB, 2008. Available from: URL: http://www.cimzia.com
30 Mahadevan U, Cucchiara S, Hyams JS, Steinitzurw F, Nuiti F, Travis SP, Sandborn WJ, Colombel JF. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2011; 106: 214-23; quiz 224 [PMID: 21157441 DOI: 10.1038/ajg.2010.464]
31 Chambers CD, Johnson DL, Jones KL. Pregnancy outcome in women exposed to anti-TNF medications: the OTIS Rheumatoid Arthritis in Pregnancy Study. Arthritis Rheum 2004; 50: 5479
32 Mahadevan U, Terdman JP, Church J. Infliximab levels in infants born to women with inflammatory bowel disease. Gastroenterol 2007; 132: A144
33 Berthelot JM, De Bandt M, Goupille P, Solau-Cervais E, Lioté F, Goeb V, Azais I, Martin A, Pallet-Prades B, Maugars Y, Mariette X. Exposure to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 2009; 76: 28-34 [PMID: 19055799 DOI: 10.1016/j.jbspin.2008.04.016]
34 Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003; 30: 241-246 [PMID: 12563675]
36 Correa LM, Bonilha DQ, Ramos JD, Ambrogini O, Misspumten SJ. Inflammatory bowel disease and pregnancy: report of two cases treated with infliximab and a review of the literature. Eur J Gastroenterol Hepatol 2010; 22: 1260-1264 [PMID: 20671599 DOI: 10.1097/MEG.0b013e282359434a]
37 Hyrich KL, Symmons DP, Watson KD, Silman AJ. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Rheumatol 2006; 54: 2701-2702 [PMID: 16871549 DOI: 10.1002/art.22028]
38 Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn’s disease before and after delivery. J Clin Gastroenterol 2009; 43: 613-616 [PMID: 19142167 DOI: 10.1097/MCG.0b013e31817f9367]
39 Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am J Obstet Gynecol 2004; 99: 2385-2392 [PMID: 15751587 DOI: 10.1016/j.ajog.2004.03.0186]
40 Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdman JP, Binion DG. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn’s disease. Aliment Pharmacol Ther 2005; 21: 733-738 [PMID: 15771759 DOI: 10.1111/j.1365-2036.2005.02405.x]
41 Rosner I, Haddad A, Boulman N, Feld J, Avshovich N, Slobodin G, Rozenbaum M. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha inhibitor therapy. Rheumatology (Oxford) 2007; 46: 1508; author reply 1508-1509 [PMID: 17684027 DOI: 10.1093/rheumatology/ kem068]
42 Schnitzler F, Fickler HH, Ferrante M, Noman M, Van Assche GA, Spitz B, Vermeire S, Rutgeerts P. Intentional treatment with infliximab during pregnancy in women with inflammatory bowel disease. Gastroenterol 2007; 132: A144
43 Weber-Schoendorfer C, Fritzsche J, Schaefe. Pregnancy outcomes in women exposed to adalimumab or infliximab: The experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy. Reprod Toxicol 2011; 31: A267-268 [DOI: 10.1016/j.reprotox.2010.12.052]
44 Zelinova Z, de Haar C, de Ridder L, Pierik MJ, Kuipers EJ, Mohr DJ. Pregnancy outcome in women exposed to anti-TNF medication: the ITIS pregnancy study. Paediatric & Adolescent Medicine Australian Society for Reproductive Physiology, 2010; 33: 374-375 [PMID: 18846021]
45 Angelucci E, Cesaroni M, Vernia P. Inadvertent conception during concomitant treatment with infliximab and methotrexate in a patient with Crohn’s disease: is the game worth the candle? Inflamm Bowel Dis 2010; 16: 1641-1642 [PMID: 20829276]

Marchioni RM et al. TNF-α inhibitor therapy and fetal risk

WJC | www.wjgnet.com

May 7, 2013 | Volume 19 | Issue 17

2599
Angelucci E, Cocco A, Viscido A, Caprilli R. Safe use of infliximab for the treatment of fistulizing Crohn’s disease during pregnancy within 3 months of conception. Inflamm Bowel Dis 2010; 16: 1849-1854 [PMID: 20474211 DOI: 10.1002/ibd.20219]

Antoni C, Dechant H, Hans-Martin Lorenz PD, Wenderler J, Ogilvie A, Lueftl M, Kalden-Nemeth D, Kalden JR, Manger B. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002; 47: 506-512 [PMID: 12382299 DOI: 10.1002/art.10671]

Araki K, Takeuchi Y, Oishi C, Imawari M. The impact of disease activity of Crohn’s disease during pregnancy on fetal growth. Clin J Gastroenterol 2010; 3: 179-181 [DOI: 10.1007/s12328-010-0158-9]

Aratari A, Margagnoni G, Koch M, Papi C. Intentional infliximab use during pregnancy for severe steroid-refractory ulcerative colitis. J Crohns Colitis 2011; 5: 262 [DOI: 10.1016/j.jcrc.2011.02.004]

Burt MJ, Frizelle FA, Barbeatz GO. Pregnancy and exposure to infliximab (anti-tumor necrosis factor-alpha monoclonal antibody). J Gastroenterol Hepatol 2003; 18: 465-466 [PMID: 12653902 DOI: 10.1046/j.1440-1746.2003.02983.x]

Chaparro M, Gisbert JP. Successful use of infliximab for perianal Crohn’s disease in pregnancy. Inflamm Bowel Dis 2011; 17: 868-869 [PMID: 20564533 DOI: 10.1002/ibd.21368]

Cheent K, Barco D, Alomar A. Treatment of psoriasis with anti-TNF-α antibodies in women during pregnancy. J Eur Acad Dermatol Venereol 2005.065417

Hou JK, Maheadevan U. A 24-year-old pregnant woman with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009; 7: 944-947 [PMID: 19410166 DOI: 10.1016/j.cgh.2009.04.022]

James RL, Pearson LL. Successful treatment of pregnancy-triggered Crohn’s disease complicated by severe recurrent life-threatening gastrointestinal bleeding. Am J Gastroenterol 2001; 96: 5295 [DOI: 10.1111/j.1572-0241.2001.tb01156.x]

Kinder AJ, Edwards J, Samanta A, Nichol F. Pregnancy in a patient with Crohn’s disease. Clin Gastroenterol Hepatol 2008; 6: 475-476 [PMID: 19059982 DOI: 10.1016/j.cgh.2009.11.023]

Koc M, Takeuchi Y, Oishi C, Imawari M. The impact of disease activity of Crohn’s disease during pregnancy on fetal growth. Clin J Gastroenterol 2010; 3: 179-181 [DOI: 10.1007/s12328-010-0158-9]

Liu Y, Kung EM, Chamberlain DL, Lai SC, Lee CF, Tillack C, Göke B, Ochsenkühn T, Seiderer J. Safety of infliximab use during pregnancy for severe steroid-refractory ulcerative colitis. J Crohns Colitis 2012; 6: 358-361 [PMID: 22405174 DOI: 10.1016/j.jcct.2011.10.002]

Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol 2008; 14: 3085-3087 [PMID: 18494064 DOI: 10.378/j/wjg.v14.i3085]

Tursi A. Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn’s disease. Dig Liver Dis 2006; 38: 439-440 [PMID: 16563889 DOI: 10.1016/j.dld.2006.01.0177]

Wibaux C, Andrei I, Paccou J, Philippe P, Biver E, Duquesnoy B, Filipo RM. Pregnancy during TNFalpha antagonist therapy: beware the rifampin-oral contraceptive interaction. Report of two cases. Joint Bone Spine 2010; 77: 268-270 [PMID: 20474852 DOI: 10.1016/j.jbspin.2010.02.001]

Xirochakis E, Karantanos P, Tsartsiil A, Karkatzos E. Pregnancy and Crohn’s disease: Infliximab induction therapy, accidental conception, pregnancy outcome and postpartum complications. Annals Gastroenterol 2006; 19: 138-140

Johnson DJ, Jones KL, Chambers CD, Salas E. Pregnancy outcomes in women exposed to Adalimumab: The OTIS Autoimmune Diseases in Pregnancy Project. Gastroenterol 2009; 136 S1: A27 [DOI: 10.1001/s0016-6855(09)60125-6]

Johnson DL, Jones KL, Jimenez J, Mirrasoul N, Salas E, Chambers CD. Pregnancy outcomes in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project. Available from: URL: http://www.otispregnancy.org/readResource.php?r=108643

Abdul Wahab NA, Harkin R. Humira in pregnancy for Crohn’s disease: A case report. Ir J Med Sci 2011; 180: S132 [DOI: 10.1185/1845-011-0697-1]

Ben-Horin S, Yavvori M, Katz L, Picard O, Fudim E, Chowers Y, Lang A. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 2010; 8: 475-476 [PMID: 20005982 DOI: 10.1016/j.cgh.2009.11.023]

Bosworth BP, Inra J, Eswaran S, Scherf EJ. Failed use of adalimumab in maintaining remission in Crohn’s disease during pregnancy. Am J Gastroenterol 2007; 102: S322 [DOI: 10.1111/j.1572-0241.2007.01491_7.x]

Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn’s disease of an ileoanal pouch during pregnancy. Dig Dis Sci 2006; 51: 2045-2047 [PMID: 17099112 DOI: 10.1007/s10620-006-9452-2]

Dessi-nioti C, Stefanaki I, Stratigos AJ, Kostaki M, Katsambas A, Antoniou C. Pregnancy during adalimumab use for psoriasis. J Eur Acad Dermatol Venereol 2011; 25: 738-739 [PMID: 20569288 DOI: 10.1111/j.1468-3083.2010.03756.x]

Jørgens M, Brand S, Fiolik L, Hübenner C, Hashbargen U, Beigel F, Tiffack C, Göke B, Ochsenuhn T, Seiderer J. Safety of adalimumab in Crohn’s disease during pregnancy: case report and a review of the literature. Inflamm Bowel Dis 2010; 16: 1634-1636 [PMID: 20027647 DOI: 10.1002/ibd.21198]

Kraemer B, Abele H, Hahn M, Rajab T, Kraemer E, Wallwein D, Becker S. A successful pregnancy in a patient with Takayasu’s arteritis. Hypertens Pregnancy 2008; 27: 247-252 [PMID: 18696353 DOI: 10.1016/j.hypertenergyn.2008.06.001]

Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (Humira) for Crohn’s disease in pregnancy. Inflamm Bowel Dis 2006; 12: 827-828 [PMID: 16917259 DOI: 10.1097/01.MIB.0000210512-00002]

Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Pregnancy in patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007; 46: 695-698 [PMID: 17158212 DOI: 10.1093/rheumatology/ke400]

Vesga L, Terdinan JP, Maheadevan U. Adalimumab use in pregnancy. Gut 2005; 54: 890 [PMID: 15888806 DOI: 10.1136/gut.2005.05417]

Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 2009; 104: 228-233 [PMID: 19098873 DOI: 10.1038/ajg.2008.71]

Maheadevan U, Abreu MT. Certolizumab use in pregnancy: low levels detected in cord blood. Am J Gastroenterol 2009; 104: 228-233 [PMID: 19098873 DOI: 10.1038/ajg.2008.71]
Marchioni RM et al. TNF-α inhibitor therapy and fetal risk
Marchioni RM et al. TNF-α inhibitor therapy and fetal risk

100 Kornfeld D, Cnattingius S, Ekbom A. Pregnancy outcomes in women with inflammatory bowel disease—a population-based cohort study. *Am J Obstet Gynecol* 1997; 177: 942-946 [PMID: 9269849]

101 Fonager K, Sørensen HT, Olsen J, Dahlerup JF, Rasmussen SN. Pregnancy outcome for women with Crohn’s disease: a follow-up study based on linkage between national registries. *Am J Gastroenterol* 1998; 93: 2426-2430 [PMID: 9860403 DOI: 10.1111/j.1572-0241.1998.00698.x]

102 Mahadevan U, Kane S. American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy. *Gastroenterology* 2006; 131: 278-282 [PMID: 16831610 DOI: 10.1053/j.gastro.2006.04.048]

103 Seirafi M, Treton X, De VroeyB, Cosnes J, Roblin X, Allez M, Marteau P, De Vos M, Flamant M, Laharie D, Savoye G, Peyrin-Biroulet L, Brixi-Benmansour H, Mathieu N, Bouhnik Y, GETAID. Anti-TNF therapy and pregnancy in inflammatory bowel disease: A prospective cohort study from the GETAID. *Gastroenterol* 2011; 140: S175 [DOI: 10.1016/S0016-5085(11)00708-7]

104 Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2013; 11: 286-92; quiz e24 [PMID: 23200982 DOI: 10.1016/j.cgh.2012.11.011]

105 Mahadevan U, Martin CF, Sandler RS, Kane SV, Dubinsky M, Lewis JD, Sandborn WJ, Sands BE. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. *Gastroenterol* 2012; 14: S149

P- Reviewers Mayer RB, Ehrenpreis ED  S- Editor Gou SX  L- Editor A  E- Editor Zhang DN